IXC 5.56% 7.6¢ invex therapeutics ltd

Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-150

  1. 343 Posts.
    lightbulb Created with Sketch. 23
    This company should have gone private and now the issue is that any take over offer will be priced at a 35% uplift on current average share price.
 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.